Schneider, Ruth http://orcid.org/0000-0002-0997-2725
Matusche, Britta
Genç, Erhan
Gold, Ralf
Bellenberg, Barbara
Lukas, Carsten
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01GI1601I)
Deutsche Forschungsgemeinschaft (GE 2777/2-1)
Ruhr-Universität Bochum
Article History
Received: 25 August 2020
Accepted: 26 February 2021
First Online: 31 March 2021
Declarations
:
: R. Schneider has received consulting and speakers honoraria from Biogen Idec GmBH and Roche Pharma AG & has received research scientific grant support from Novartis Pharma. R. Gold has received compensation for serving as a consultant or speaker from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; he, or the institution he works for, has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience; he has also received honoraria as a Journal Editor from SAGE and Thieme Verlag. B. Bellenberg received financial support by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I. C. Lukas received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I, has received consulting and speaker’s honoraria from Biogen Idec, Bayer Schering, Daiichi Sanykyo, Merck Serono, Novartis, Sanofi, Genzyme and TEVA. B. Matusche and E. Genç declare that they have no competing interests.
: The study was approved by the local ethics committee of the Ruhr University Bochum (Approval No. 3714-10). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Consent to participate: all participants gave written informed consent for participation in the study, which includes dissemination of the results.